Mumbai : In a major development for India’s pharmaceutical and biotechnology sector, Biocon Limited, a leading biopharmaceutical company, has expressed keen interest in investing in an insulin manufacturing project in Maharashtra near Pune. Chief Minister Devendra Fadnavis welcomed the move, assuring full support from the state government for the proposed investment.
The announcement came during a special meeting held at the WAVES 2025 Audio-Visual Entertainment Summit at Jio World Centre, Bandra Kurla Complex, where CM Fadnavis met with Biocon Executive Chairperson Kiran Shaw Mazumdar.
“This proposed investment from a globally recognized company like Biocon is a matter of pride for Maharashtra. It will boost the state’s presence in pharmaceutical and biotech manufacturing,” said CM Fadnavis, adding that state officials will initiate preliminary discussions with Biocon’s management to take the project forward.
Kiran Mazumdar-Shaw shared that Biocon is poised to become the global leader in insulin production, and the company is exploring the possibility of setting up its manufacturing facility in the Pune region. The project is expected to generate thousands of employment opportunities, enhance healthcare access, and strengthen India’s position as a global hub for life sciences and drug manufacturing.
The government’s proactive policies and Maharashtra’s robust industrial ecosystem have made the state an attractive destination for high-impact investments in pharma and biotechnology sectors.
